ProShare Advisors
MGNX icon

ProShare Advisors’s MacroGenics MGNX Stock Holding History

ProShare Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,137
Closed -$20.5K – 2143
2025
Q1 		$20.5K Sell
16,137
-4,147
-20% -$10.8K ﹤0.01% 2036
2024
Q4 		$65.9K Buy
20,284
+4,963
+32% +$17.9K ﹤0.01% 2145
2024
Q3 		$50.4K Buy
15,321
+3,303
+27% +$12.9K ﹤0.01% 1977
2024
Q2 		$51.1K Sell
12,018
-3,264
-21% -$31.8K ﹤0.01% 1747
2024
Q1 		$225K Buy
15,282
+1,246
+9% +$18.8K ﹤0.01% 1612
2023
Q4 		$135K Buy
14,036
+2,081
+17% +$14.4K ﹤0.01% 1736
2023
Q3 		$55.7K Buy
11,955
+38
+0.3% +$189 ﹤0.01% 1707
2023
Q2 		$63.8K Buy
11,917
+561
+5% +$3.46K ﹤0.01% 1748
2023
Q1 		$81.4K Sell
11,356
-1,485
-12% -$8.94K ﹤0.01% 1624
2022
Q4 		$86.2K Buy
12,841
+1,026
+9% +$5.63K ﹤0.01% 1676
2022
Q3 		$41K Buy
11,815
+266
+2% +$1.02K ﹤0.01% 1677
2022
Q2 		$34K Sell
11,549
-6,055
-34% -$31.8K ﹤0.01% 1743
2022
Q1 		$156K Sell
17,604
-4,114
-19% -$45.4K ﹤0.01% 1946
2021
Q4 		$348K Buy
21,718
+972
+5% +$18.3K ﹤0.01% 1696
2021
Q3 		$434K Sell
20,746
-5,345
-20% -$129K ﹤0.01% 1292
2021
Q2 		$701K Buy
26,091
+3,649
+16% +$107K ﹤0.01% 1267
2021
Q1 		$715K Buy
22,442
+1,619
+8% +$39.3K ﹤0.01% 1201
2020
Q4 		$476K Buy
20,823
+5,629
+37% +$130K ﹤0.01% 1309
2020
Q3 		$383K Buy
15,194
+843
+6% +$23K ﹤0.01% 1047
2020
Q2 		$401K Buy
+14,351
New +$249K ﹤0.01% 1063
2020
Q1 		– Sell
-17,039
Closed -$185K – 1418
2019
Q4 		$185K Sell
17,039
-1,626
-9% -$16.1K ﹤0.01% 1610
2019
Q3 		$238K Buy
18,665
+273
+1% +$3.93K ﹤0.01% 1339
2019
Q2 		$312K Sell
18,392
-2,443
-12% -$42K ﹤0.01% 1220
2019
Q1 		$375K Buy
20,835
+2,380
+13% +$41.1K ﹤0.01% 1153
2018
Q4 		$234K Sell
18,455
-3,563
-16% -$59.8K ﹤0.01% 1286
2018
Q3 		$472K Sell
22,018
-881
-4% -$18.8K ﹤0.01% 1134
2018
Q2 		$473K Buy
22,899
+1,495
+7% +$33.7K ﹤0.01% 1148
2018
Q1 		$539K Sell
21,404
-3,466
-14% -$84.2K ﹤0.01% 1066
2017
Q4 		$473K Buy
24,870
+1,814
+8% +$33.9K ﹤0.01% 1161
2017
Q3 		$426K Buy
23,056
+2,145
+10% +$37.2K ﹤0.01% 1026
2017
Q2 		$366K Sell
20,911
-1,426
-6% -$27.2K ﹤0.01% 1071
2017
Q1 		$415K Sell
22,337
-5,799
-21% -$112K ﹤0.01% 1088
2016
Q4 		$575K Buy
28,136
+3,092
+12% +$77.8K 0.01% 1010
2016
Q3 		$749K Sell
25,044
-4,570
-15% -$136K 0.01% 777
2016
Q2 		$799K Buy
29,614
+200
+0.7% +$4.51K 0.01% 786
2016
Q1 		$552K Sell
29,414
-2,765
-9% -$52.6K 0.01% 954
2015
Q4 		$997K Buy
32,179
+3,098
+11% +$94.1K 0.01% 737
2015
Q3 		$623K Buy
29,081
+1,523
+6% +$47.8K 0.01% 857
2015
Q2 		$1.05M Buy
27,558
+1,304
+5% +$42.9K 0.01% 752
2015
Q1 		$824K Buy
26,254
+3,558
+16% +$121K 0.01% 945
2014
Q4 		$796K Buy
+22,696
New +$566K 0.01% 967
2014
Q3 		– Sell
-9,736
Closed -$212K – 2339
2014
Q2 		$212K Buy
+9,736
New +$205K ﹤0.01% 2134

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ProShare Advisors's MGNX Position: Q2 2025 in Review

ProShare Advisors sold out of MacroGenics (MGNX) in Q2 2025, closing a stake of 16,137 shares — an estimated $20.5K sold.

ProShare Advisors first reported a position in MGNX in Q2 2014 and held it in 42 quarters. The position peaked at $1.05M in Q2 2015. 112 funds tracked by Wall St. Rank hold MGNX as of Q2 2025.

  • ProShare Advisors reported no remaining MacroGenics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 16,137 MacroGenics shares in Q2 2025, an estimated $20.5K.
  • ProShare Advisors first reported a position in MacroGenics in Q2 2014 and held it in 42 quarters.
  • ProShare Advisors's MacroGenics position peaked at $1.05M in Q2 2015.
  • 112 funds tracked by Wall St. Rank held MacroGenics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.